Department of Traditional Chinese Medical Gynecology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Medicine (Baltimore). 2022 Dec 23;101(51):e32419. doi: 10.1097/MD.0000000000032419.
Infertility has become a global public health issue. In vitro fertilization and embryo transfer (IVF-ET) is widely performed as an infertility treatment. However, a significant number of infertile women continue to experience serial implantation failure, despite the high quality of the transferred embryos. Jian-Pi-An-Tai formula is an experience formula in treating threatened abortion in our team. It has also been used to treat infertile women after embryo transfer and shows superiority compared to single use of conventional western medicine. However, the of evidence on its effective in treating infertile women undergo IVF-ET is lacking.
This randomized controlled trial (RCT) will be carried out in Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University planning to recruit 180 infertile patients undergoing IVF-ET with the type of deficiency of both the spleen and kidney. The control group will be treated by conventional western medicine and the treatment group will use conventional western medicine plus Jian-Pi-An-Tai formula. The primary outcomes will include Embryo implantation rate, Clinical pregnancy rate, Persistent pregnancy rate; and the secondary outcomes will include TCM symptom score and reproductive hormones. Safety evaluation will be recorded during the whole study. All data in this RCT will be analyzed by SPSS 23.0 software. This study has been approved by the Research Ethics Committee of the Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University (2022KY130).
The results of this RCT will contribute to provide scientific and rigorous evidence for the efficacy and safety of Jian-Pi-An-Tai formula in treating infertile women undergo IVF-ET. And the results from this RCT will be published in a relevant journal after finished.
不孕不育已成为全球性公共卫生问题。体外受精-胚胎移植(IVF-ET)被广泛应用于治疗不孕不育。然而,尽管移植胚胎的质量很高,仍有相当数量的不孕女性继续经历反复着床失败。健脾安胎方是我们团队在治疗先兆流产方面的经验方。它也被用于治疗胚胎移植后的不孕女性,与单一使用常规西药相比具有优势。然而,其在治疗接受 IVF-ET 的不孕女性方面的疗效证据不足。
本随机对照试验(RCT)将在浙江中医药大学附属杭州中医院进行,计划招募 180 名接受 IVF-ET 的脾肾两虚型不孕患者。对照组采用常规西药治疗,治疗组采用常规西药加健脾安胎方。主要结局指标包括胚胎着床率、临床妊娠率、持续妊娠率;次要结局指标包括中医症状评分和生殖激素。整个研究过程中记录安全性评估。本 RCT 中的所有数据均采用 SPSS 23.0 软件进行分析。本研究已获得浙江中医药大学附属杭州中医院伦理委员会的批准(2022KY130)。
本 RCT 的结果将为健脾安胎方治疗接受 IVF-ET 的不孕女性的疗效和安全性提供科学严谨的证据。完成后,本 RCT 的结果将在相关期刊上发表。